CRS0540 Gram-positives

Preclinical program targeting antibiotic-resistant Gram-positive infections.

  • MRSA skin infections
  • MRSA & PRSP pneumonia
  • Group A strep
  • Group B strep and Listeria neonatal infections
  • VRE bacteremia
  • Anthrax
  • Listeria food poisoning




Ongoing Studies




News / Updates

CRS0540 Gram-positives Overview

We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance. CRS0540 exhibits broad spectrum activity against all clinically significant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), Streptococcus agalactiae (Group B strep), vancomycin-resistant Enterococci (VRE), Bacillus anthracis (anthrax), and Listeria monocytogenes.

Key Areas of Study

  • Novel mechanism of action based on inhibition of PolC, an essential DNA polymerase
  • Oral bioavailability, facilitating outpatient treatment
  • Bactericidal activity
  • Low spontaneous resistance rates
  • In vivo efficacy in preclinical models of infection
  • Low propensity for toxicity observed in vitro and in vivo

Ongoing CRS0540 Gram-positives Studies

Novel antibacterial candidate CRS0540 is still in pre-clinical development, so no clinical studies are available for this drug candidate at the moment. Please check back soon for further updates.

CRS0540 News / Updates

Become a Part of This Project

Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.


Have a question or comment? Follow the link below to contact us about general inquiries.


Find work in a team-oriented environment at one of the leading Colorado pharma companies.


If you're interested in becoming an investor to help fund our research and development, contact us today.